bioAffinity says CyPath Lung test sales more than double through Q3 2026

Bitget2026/10/06 13:19

bioAffinity Technologies reported CyPath Lung test sales rose more than 100% through Q3 2026 versus the prior-year period. Ordering physicians increased 89% in Q3 versus Q3 2025. Physicians who ordered through Q3 2025 lifted test volume 48% year over year. Delivered 1,620 tests through Q3 versus 775 a year earlier. Distribution agreement with Veteran-Owned AvMEDICAL targets broader access in government healthcare, including the Department of Veterans Affairs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006386482) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Chaincatcher•2026/10/10 07:19

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21

Gold price fluctuates repeatedly, institutions believe the timing for investment has arrived

新浪财经•2026/10/10 06:21

Apple iPhone Duo increases orders by 30%, total order volume for iPhone 18 Pro series remains unchanged

华尔街见闻•2026/10/10 06:19